505 related articles for article (PubMed ID: 15001676)
21. Transport mechanisms of 3-[123I]iodo-alpha-methyl-L-tyrosine in a human glioma cell line: comparison with [3H]methyl]-L-methionine.
Langen KJ; Mühlensiepen H; Holschbach M; Hautzel H; Jansen P; Coenen HH
J Nucl Med; 2000 Jul; 41(7):1250-5. PubMed ID: 10914918
[TBL] [Abstract][Full Text] [Related]
22. Preferred transport of O-(2-[18F]fluoroethyl)-D-tyrosine (D-FET) into the porcine brain.
Makrides V; Bauer R; Weber W; Wester HJ; Fischer S; Hinz R; Huggel K; Opfermann T; Herzau M; Ganapathy V; Verrey F; Brust P
Brain Res; 2007 May; 1147():25-33. PubMed ID: 17343835
[TBL] [Abstract][Full Text] [Related]
23. Influence of Dexamethasone on O-(2-[
Stegmayr C; Stoffels G; Kops ER; Lohmann P; Galldiks N; Shah NJ; Neumaier B; Langen KJ
Mol Imaging Biol; 2019 Feb; 21(1):168-174. PubMed ID: 29845426
[TBL] [Abstract][Full Text] [Related]
24. Reproducibility of O-(2-(18)F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas.
Stegmayr C; Schöneck M; Oliveira D; Willuweit A; Filss C; Galldiks N; Shah NJ; Coenen HH; Langen KJ
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1115-23. PubMed ID: 26646781
[TBL] [Abstract][Full Text] [Related]
25. The usefulness of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents.
Dunkl V; Cleff C; Stoffels G; Judov N; Sarikaya-Seiwert S; Law I; Bøgeskov L; Nysom K; Andersen SB; Steiger HJ; Fink GR; Reifenberger G; Shah NJ; Coenen HH; Langen KJ; Galldiks N
J Nucl Med; 2015 Jan; 56(1):88-92. PubMed ID: 25525183
[TBL] [Abstract][Full Text] [Related]
26. Assessment of clinical usefulness of 131I alpha-methyl-tyrosine and fused SPECT/MRI imaging for diagnostics of recurrent cerebral gliomas.
Górska-Chrzastek M; Grzelak P; Bieńkiewicz M; Tybor K; Zakrzewska E; Mikołajczak R; Stefańczyk L; Kuśmierek J
Nucl Med Rev Cent East Eur; 2004; 7(2):135-41. PubMed ID: 15968600
[TBL] [Abstract][Full Text] [Related]
27. Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging.
Stadlbauer A; Prante O; Nimsky C; Salomonowitz E; Buchfelder M; Kuwert T; Linke R; Ganslandt O
J Nucl Med; 2008 May; 49(5):721-9. PubMed ID: 18413402
[TBL] [Abstract][Full Text] [Related]
28. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
[TBL] [Abstract][Full Text] [Related]
29. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
[TBL] [Abstract][Full Text] [Related]
30. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy.
Floeth FW; Pauleit D; Wittsack HJ; Langen KJ; Reifenberger G; Hamacher K; Messing-Jünger M; Zilles K; Weber F; Stummer W; Steiger HJ; Woebker G; Müller HW; Coenen H; Sabel M
J Neurosurg; 2005 Feb; 102(2):318-27. PubMed ID: 15739561
[TBL] [Abstract][Full Text] [Related]
31. Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18F-Fluoroethyl-l-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic.
Hutterer M; Ebner Y; Riemenschneider MJ; Willuweit A; McCoy M; Egger B; Schröder M; Wendl C; Hellwig D; Grosse J; Menhart K; Proescholdt M; Fritsch B; Urbach H; Stockhammer G; Roelcke U; Galldiks N; Meyer PT; Langen KJ; Hau P; Trinka E
J Nucl Med; 2017 Jan; 58(1):129-137. PubMed ID: 27469356
[TBL] [Abstract][Full Text] [Related]
32. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours.
Weckesser M; Langen KJ; Rickert CH; Kloska S; Straeter R; Hamacher K; Kurlemann G; Wassmann H; Coenen HH; Schober O
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):422-9. PubMed ID: 15650870
[TBL] [Abstract][Full Text] [Related]
33. Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-¹⁸Fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful?
Piroth MD; Liebenstund S; Galldiks N; Stoffels G; Shah NJ; Eble MJ; Coenen HH; Langen KJ
Mol Imaging; 2013 Sep; 12(6):388-95. PubMed ID: 23981784
[TBL] [Abstract][Full Text] [Related]
34. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer.
Pauleit D; Zimmermann A; Stoffels G; Bauer D; Risse J; Flüss MO; Hamacher K; Coenen HH; Langen KJ
J Nucl Med; 2006 Feb; 47(2):256-61. PubMed ID: 16455631
[TBL] [Abstract][Full Text] [Related]
35. 18F-FET PET differentiation of ring-enhancing brain lesions.
Floeth FW; Pauleit D; Sabel M; Reifenberger G; Stoffels G; Stummer W; Rommel F; Hamacher K; Langen KJ
J Nucl Med; 2006 May; 47(5):776-82. PubMed ID: 16644747
[TBL] [Abstract][Full Text] [Related]
36. Influence of Bevacizumab on Blood-Brain Barrier Permeability and
Stegmayr C; Oliveira D; Niemietz N; Willuweit A; Lohmann P; Galldiks N; Shah NJ; Ermert J; Langen KJ
J Nucl Med; 2017 May; 58(5):700-705. PubMed ID: 28153956
[TBL] [Abstract][Full Text] [Related]
37. Uptake and tracer kinetics of O-(2-(18)F-fluoroethyl)-L-tyrosine in meningiomas: preliminary results.
Cornelius JF; Stoffels G; Filß C; Galldiks N; Slotty P; Kamp M; el Khatib M; Hänggi D; Sabel M; Felsberg J; Steiger HJ; Coenen HH; Shah NJ; Langen KJ
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):459-67. PubMed ID: 25331459
[TBL] [Abstract][Full Text] [Related]
38. L-3-[123I]iodo-alpha-methyl-tyrosine SPECT in non-small cell lung cancer: preliminary observations.
Jager PL; Groen HJ; van der Leest A; van Putten JW; Pieterman RM; de Vries EG; Piers DA
J Nucl Med; 2001 Apr; 42(4):579-85. PubMed ID: 11337545
[TBL] [Abstract][Full Text] [Related]
39. Treatment-Related Uptake of
Geisler S; Stegmayr C; Niemitz N; Lohmann P; Rapp M; Stoffels G; Willuweit A; Galldiks N; Filss C; Sabel MC; Coenen HH; Shah NJ; Langen KJ
J Nucl Med; 2019 Oct; 60(10):1373-1379. PubMed ID: 30850492
[TBL] [Abstract][Full Text] [Related]
40. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
